Detailed Information

Cited 17 time in webofscience Cited 17 time in scopus
Metadata Downloads

Extraosseous osteosarcoma: Single institutional experience in Korea

Authors
Lee, SLee, MRLee, SJAhn, HKYi, JYi, SYSeo, SWSung, KSPark, JOLee, J
Issue Date
Jun-2010
Publisher
Blackwell Pub. Asia
Keywords
chemotherapy; extraosseous osteosarcoma; prognosis
Citation
Asia-Pacific Journal of Clinical Oncology, v.6, no.2, pp 126 - 129
Pages
4
Indexed
SCIE
SCOPUS
Journal Title
Asia-Pacific Journal of Clinical Oncology
Volume
6
Number
2
Start Page
126
End Page
129
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/43715
DOI
10.1111/j.1743-7563.2010.01278.x
ISSN
1743-7555
1743-7563
Abstract
Aim: Extraosseous osteosarcoma (EOO) is a rare soft tissue form of osteosarcoma without involvement of the skeletal system. Due to the rarity of disease, its clinical features and optimal treatment are yet to be defined. Methods: Between 1 January 1999 and 30 June 2008 ten patients were pathologically confirmed with extra-skeletal osteosarcoma. A retrospective analysis of the ten patients was performed. Results: The anatomical distribution of the osteosarcomas was as follows: lower extremities (n = 3), upper extremities (n = 2), breast (n = 2), lung (n = 1), cheek (n = 1) and retroperitoneum (n = 1). Nine patients initially underwent resection of the primary mass. One patient, who received six cycles of adjuvant doxorubicin and cisplatin chemotherapy was alive in remission at 42.6 months. One patient with postoperative radiotherapy after curative surgery was alive in remission at 6.2 months. However, all three patients who received curative resection but no postoperative radiotherapy or chemotherapy died of the disease at 10.7, 11.1 and 15.6 months after surgery. The median time to failure was only 4.4 months (95% CI, 0.6, 8.2 months) and the median survival time of all patients was only 11.1 months (95% CI, 5.6, 16.6 months). At the time of analysis, seven patients were dead and all died of the disease recurrence. Conclusion: EOO should be treated as a soft tissue sarcoma with aggressive behavior and multimodality treatment should be actively sought to improve treatment outcome. The impact of adjuvant chemotherapy on survival of EOO needs further investigation.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Medical Oncology and Hematology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Lee, SOOHYEON photo

Lee, SOOHYEON
Anam Hospital (Department of Medical Oncology and Hematology, Anam Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE